Search

Your search keyword '"Kellokumpu-Lehtinen, Pirkko Liisa"' showing total 631 results
Start Over Author "Kellokumpu-Lehtinen, Pirkko Liisa"
631 results on '"Kellokumpu-Lehtinen, Pirkko Liisa"'

4. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

Author

Tolaney, Sara M., Guarneri, Valentina, Seo, Jae Hong, Cruz, Josefina, Abreu, Miguel Henriques, Takahashi, Masato, Barrios, Carlos, McIntyre, Kristi, Wei, Ran, Munoz, Maria, Antonio, Belen San, Liepa, Astra M., Martin, Miguel, Johnston, Stephen R.D., Kellokumpu-Lehtinen, Pirkko-Liisa, and Harbeck, Nadia

Published
2024
Full Text
View/download PDF

5. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

6. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

9. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

Author

Loi, Sherene, Salgado, Roberto, Adams, Sylvia, Pruneri, Giancarlo, Francis, Prudence A., Lacroix-Triki, Magali, Joensuu, Heikki, Dieci, Maria Vittoria, Badve, Sunil, Demaria, Sandra, Gray, Robert, Munzone, Elisabetta, Drubay, Damien, Lemonnier, Jerome, Sotiriou, Christos, Kellokumpu-Lehtinen, Pirkko Liisa, Vingiani, Andrea, Gray, Kathryn, André, Fabrice, Denkert, Carsten, Piccart, Martine, Roblin, Elvire, and Michiels, Stefan

Published
2022
Full Text
View/download PDF

11. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Author

Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bossi, Alberto, Bristow, Rob, Carver, Brett, Castellano, Daniel, Chung, Byung Ha, Clarke, Noel, Daugaard, Gedske, Davis, Ian D, de Bono, Johann, dos Reis, Rodolfo Borges, Drake, Charles G, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P, Fanti, Stefano, Feng, Felix, Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Higano, Celestia S, James, Nicolas, Kantoff, Philip, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B, Kramer, Gero, Logothetis, Chris, Maluf, Fernando, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Murthy, Vedang, Oh, William, Ost, Piet, Padhani, Anwar R, Parker, Chris, Pritchard, Colin C, Roach, Mack, Rubin, Mark A, Ryan, Charles, Saad, Fred, Sartor, Oliver, Scher, Howard, Sella, Avishay, Shore, Neal, Smith, Matthew, Soule, Howard, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Tannock, Ian, Tombal, Bertrand, Valdagni, Riccardo, Wiegel, Thomas, and Omlin, Aurelius

Subjects
Cancer, Urologic Diseases, Aging, Prostate Cancer, Good Health and Well Being, Humans, Male, Neoplasm Staging, Practice Guidelines as Topic, Prostatic Neoplasms, Advanced and high-risk localized prostate cancer, Castration-naive and castration-resistant prostate cancer, Therapeutics, Consensus, Oligometastatic prostate cancer, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundIn advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.ObjectiveTo present the report of APCCC 2017.Design, setting, and participantsTen important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions.Outcome measurements and statistical analysisThe panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process.Results and limitationsVoting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data.ConclusionsThe presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them.Patient summaryThe second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.

Published
2018

12. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine

Author

Jasu, Juho, Tolonen, Teemu, Antonarakis, Emmanuel S., Beltran, Himisha, Halabi, Susan, Eisenberger, Mario A., Carducci, Michael A., Loriot, Yohann, Van der Eecken, Kim, Lolkema, Martijn, Ryan, Charles J., Taavitsainen, Sinja, Gillessen, Silke, Högnäs, Gunilla, Talvitie, Timo, Taylor, Robert J., Koskenalho, Antti, Ost, Piet, Murtola, Teemu J., Rinta-Kiikka, Irina, Tammela, Teuvo, Auvinen, Anssi, Kujala, Paula, Smith, Thomas J., Kellokumpu-Lehtinen, Pirkko-Liisa, Isaacs, William B., Nykter, Matti, Kesseli, Juha, and Bova, G. Steven

Published
2021
Full Text
View/download PDF

21. Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer

Author

Lehtomäki, Kaisa, primary, Heervä, Eetu, additional, Kellokumpu-Lehtinen, Pirkko-Liisa, additional, Mustonen, Harri, additional, Salminen, Tapio, additional, Joensuu, Heikki, additional, Hermunen, Kethe, additional, Boisen, Mogens Karsbøl, additional, Johansen, Julia Sidenius, additional, Haglund, Caj, additional, and Osterlund, Pia, additional

Published
2023
Full Text
View/download PDF

22. Supplementary Table S1 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Methods from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

24. Data from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 3 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 4 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 2 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 1 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 5 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Author

Laine, Anni, primary, Sihto, Harri, primary, Come, Christophe, primary, Rosenfeldt, Mathias T., primary, Zwolinska, Aleksandra, primary, Niemelä, Minna, primary, Khanna, Anchit, primary, Chan, Edward K., primary, Kähäri, Veli-Matti, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sansom, Owen J., primary, Evan, Gerard I., primary, Junttila, Melissa R., primary, Ryan, Kevin M., primary, Marine, Jean-Christophe, primary, Joensuu, Heikki, primary, and Westermarck, Jukka, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure S2 from p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial

Author

Sperinde, Jeff, primary, Huang, Weidong, primary, Vehtari, Aki, primary, Chenna, Ahmed, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Winslow, John, primary, Bono, Petri, primary, Lie, Yolanda S., primary, Petropoulos, Christos J., primary, Weidler, Jodi, primary, and Joensuu, Heikki, primary

Published
2023
Full Text
View/download PDF

35. Fig.S1 to S7 from CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy

Author

Turcotte, Martin, primary, Allard, David, primary, Mittal, Deepak, primary, Bareche, Yacine, primary, Buisseret, Laurence, primary, José, Vinu, primary, Pommey, Sandra, primary, Delisle, Vincent, primary, Loi, Sherene, primary, Joensuu, Heikki, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sotiriou, Christos, primary, Smyth, Mark J., primary, and Stagg, John, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 1 from p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial

Author

Sperinde, Jeff, primary, Huang, Weidong, primary, Vehtari, Aki, primary, Chenna, Ahmed, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Winslow, John, primary, Bono, Petri, primary, Lie, Yolanda S., primary, Petropoulos, Christos J., primary, Weidler, Jodi, primary, and Joensuu, Heikki, primary

Published
2023
Full Text
View/download PDF

37. Data from CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy

Author

Turcotte, Martin, primary, Allard, David, primary, Mittal, Deepak, primary, Bareche, Yacine, primary, Buisseret, Laurence, primary, José, Vinu, primary, Pommey, Sandra, primary, Delisle, Vincent, primary, Loi, Sherene, primary, Joensuu, Heikki, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sotiriou, Christos, primary, Smyth, Mark J., primary, and Stagg, John, primary

Published
2023
Full Text
View/download PDF

38. Legends to Supplementary Figures from CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy

Author

Turcotte, Martin, primary, Allard, David, primary, Mittal, Deepak, primary, Bareche, Yacine, primary, Buisseret, Laurence, primary, José, Vinu, primary, Pommey, Sandra, primary, Delisle, Vincent, primary, Loi, Sherene, primary, Joensuu, Heikki, primary, Kellokumpu-Lehtinen, Pirkko-Liisa, primary, Sotiriou, Christos, primary, Smyth, Mark J., primary, and Stagg, John, primary

Published
2023
Full Text
View/download PDF

47. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Author

Cortés, Javier, Dieras, Véronique, Ro, Jungsil, Barriere, Jérôme, Bachelot, Thomas, Hurvitz, Sara, Le Rhun, Emilie, Espié, Marc, Kim, Sung-Bae, Schneeweiss, Andreas, Sohn, Joo Hyuk, Nabholtz, Jean-Marc, Kellokumpu-Lehtinen, Pirkko-Liisa, Taguchi, Julie, Piacentini, Federico, Ciruelos, Eva, Bono, Petri, Ould-Kaci, Mahmoud, Roux, Flavien, and Joensuu, Heikki

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results